Get the Stockscreener App
15.99
1.40%
0.22
Puretech Health Plc Adr stock is traded at $15.99, with a volume of 5,084.
It is up +1.40% in the last 24 hours and down -9.86% over the past month.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
See More
Previous Close:
$15.77
Open:
$16.13
24h Volume:
5,084
Relative Volume:
1.10
Market Cap:
$386.45M
Revenue:
$1.70M
Net Income/Loss:
$-47.01M
P/E Ratio:
-9.4059
EPS:
-1.7
Net Cash Flow:
$-157.28M
1W Performance:
+1.85%
1M Performance:
-9.86%
6M Performance:
-12.14%
1Y Performance:
-27.55%
1-Day Range:
$15.80
$16.24
1-Week Range:
$15.50
$16.24
52-Week Range:
$13.30
$24.99
Puretech Health Plc Adr Stock (PRTC) Company Profile
Name
Puretech Health Plc Adr
Sector
Industry
Phone
-
Address
-
Compare PRTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTC
Puretech Health Plc Adr
|
15.99 | 381.14M | 1.70M | -47.01M | -157.28M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.20 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.39 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.20 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.33 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Puretech Health Plc Adr Stock (PRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
Puretech Health Plc Adr Stock (PRTC) Latest News
PureTech Health (NASDAQ:PRTC) Stock Price Up 3.1%Time to Buy? - MarketBeat
PureTech Health PLC Sponsored ADR $PRTC Shares Sold by Birch Hill Investment Advisors LLC - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 100.0% in September - MarketBeat
Free cash flow per share of PureTech Health PLC Sponsored ADR – NASDAQ:PRTC - TradingView
PureTech Health (NASDAQ:PRTC) Trading Up 3.6%Here's What Happened - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Significant Growth in Short Interest - MarketBeat
PureTech Health (LON:PRTC) Shares Up 14.2% – Should You Buy? - Defense World
PureTech Health Sees Strong Market Presence in FTSE All Share - Kalkine Media
Parallel Advisors LLC Acquires 1,718 Shares of GSK PLC Sponsored ADR $GSK - Defense World
What Makes PureTech Health (PRTC) a New Buy Stock - Yahoo Finance
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Large Growth in Short Interest - MarketBeat
PureTech Health (NASDAQ:PRTC) Shares Up 4.7%Time to Buy? - MarketBeat
PureTech Health Cash Runway Extended - The Motley Fool
International Flavors & Fragrances (NYSE:IFF) & DAQO New Energy (NYSE:DQ) Critical Comparison - Defense World
Conference Calls and Individual Investors - MarketBeat
Deupirfenidone: A Potential New Standard of Care - Placera.se
PureTech launches new entity to advance IPF treatment deupirfenidone - Investing.com
PureTech Health to report half-yearly results on August 28 - Investing.com
PureTech Health to report half-yearly results on August 28 By Investing.com - Investing.com South Africa
PureTech Health (NASDAQ:PRTC) Trading Up 1.4% – Still a Buy? - Defense World
PureTech Health (NASDAQ:PRTC) Shares Down 7.3% – Here’s What Happened - Defense World
PureTech’s Seaport doses first patient in phase 2b depression study By Investing.com - Investing.com South Africa
PureTech Health names Robert Lyne as interim CEO as Chowrira departs - Investing.com
PureTech Health names Robert Lyne as interim CEO as Chowrira departs By Investing.com - Investing.com India
Big Oil's Q2 Outlook: Downstream Gains and Upstream Pains - The Globe and Mail
PureTech Health announces board leadership transition By Investing.com - Investing.com South Africa
PureTech Health announces board leadership transition - Investing.com
PureTech Health announces board chair Raju Kucherlapati steps down - Investing.com
PureTech Health issues shares to executives following RSU vesting - Investing.com
PureTech Health announces RSU vesting and share transactions by PDMR - Investing.com
PureTech set for Jefferies Global Healthcare Conference chat - Investing.com
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial - Placera.se
PureTech Health to release annual financial results April 30 - Investing.com
PureTech Health enlists Peel Hunt as joint broker - Investing.com
Invesco Ltd: Form 8.3PureTech Health PLC; Opening Position disclosure - The Manila Times
Nordic Capital XI ends pursuit of PureTech acquisition - Investing.com
PureTech Health (LSE: PRTC) Presents Promising Phase 1b Data for LYT-200 in AML and MDS at ASH 2024 - Kalkine Media
India Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Argentina Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Norway Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Japan Anti-obesity Medication Market Size & Outlook, 2030 - Grand View Research
Mexico Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Asia Pacific Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Anti-obesity Medication Market Size & Outlook, 2030 - Grand View Research
Top Biotech Stocks: Exploring Innovation Opportunities - MarketBeat
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share - FinancialContent
symbol__ Stock Quote Price and Forecast - CNN
The definitive Boston biotech layoff tracker for 2023 - The Business Journals
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
This Emerging Market Could Be The Next Big Thing In Biotech - Barchart.com
PureTech Share Price (PRTC) - London South East
Puretech Health Plc Adr Stock (PRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):